Biofer

What Biofer does

Biofer S.p.A. is an Italian pharmaceutical company founded in 1985 that develops, produces, and commercializes active pharmaceutical ingredients (APIs) across six core families: iron complexes (antianemics), heparins and glycosaminoglycans (antithrombotics), steroids (anti-shock/antiallergics), folinates (tumor adjuvants), enzymes (anti-inflammatories), and miscellaneous APIs. Manufacturing relies on two distinct process platforms — chemical synthesis (primarily for iron complexes and steroids) and biological extraction from liquids, organs, and animal tissues (for glycosaminoglycans and heparins) — with the company now expanding into chemistry-derived APIs via newly patented synthetic pathways. All production operates under GMP at the Medolla (MO) manufacturing site and research laboratories, with regulatory documentation (DMFs/ASMFs and full pharmaceutical dossiers) provided to clients.

The company sells APIs on a B2B basis to pharmaceutical manufacturers — ranging from small private firms to multinational corporations, and including government health ministries — across more than 60 countries, with a quote-based pricing model and direct enterprise sales relationships. Biofer holds AIFA and Italian Ministry of Health authorizations recognized across Europe, with ASMFs approved in nearly all jurisdictions worldwide, plus UNI EN ISO 14001 and UNI ISO 45001 certifications. The company is privately held under the coordination of parent Sts Pharma Srl, employs 120+ professionals (with R&D at roughly 10% of headcount), and operates a Milan executive office opened in September 2021 alongside its Medolla industrial base. Revenue figures are not publicly disclosed; growth signals include a +250% increase in R&D output over 2020–2022, 40+ hires over the past two years, and more than €18 million committed to new production facilities.

The business model is a single, horizontal product platform with six API categories serving multiple therapeutic indications (anemia, thrombosis, inflammation, allergy, oncology support, anti-shock). GTM is direct enterprise sales with a long qualification cycle embedded in regulatory submissions, supported by content marketing, LinkedIn presence, and email newsletter rather than consumer-facing channels. Capital stock is €802,516 i.v. — a small share-capital figure that does not represent enterprise value — and the company is in active expansion mode with a new research center under development.

Name

Biofer

Legal name

Biofer S.p.A.

Website

https://bioferspa.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

51–100 employees

Short description

Biofer S.p.A. is an Italian pharmaceutical company founded in 1985 that develops, produces, and commercializes GMP-compliant active pharmaceutical ingredients — including iron complexes, heparins, steroids, folinates, and enzymes — for sale B2B to pharmaceutical manufacturers and government health ministries in over 60 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain

Revenue model

1. Pharmaceutical API Sales: Biofer develops, manufactures, and commercializes active pharmaceutical ingredients (APIs) sold to pharmaceutical companies worldwide. The company provides Drug Master Files (DMFs) and complete pharmaceutical dossiers to support clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Biofer S.p.A. develops, manufactures, and commercializes active pharmaceutical ingredients (APIs) across six main product families: iron complexes (antianemics), heparins and glycosaminoglycans (antithrombotics), steroids (anti-shock, antiallergics), folinates (tumor adjuvants), enzymes (anti-inflammatories), and miscellaneous APIs. The company employs both chemical synthesis and biological extraction processes, and supports clients with Drug Master Files (DMFs/ASMFs) and complete pharmaceutical dossiers under strict GMP compliance.

Product overview

Biofer is an Italian pharmaceutical company that develops, produces, and commercializes active pharmaceutical ingredients (APIs). The company operates as a single unified product portfolio focused on six main families of APIs: Iron Complexes (as antianemics), Heparins and Glycosaminoglicans (as antithrombotics), Steroids (as anti-shock and antiallergics), Folinates (as tumor adjuvants), Enzymes (as anti-inflammatories), and Miscellaneous APIs. The product portfolio also includes supporting services such as Drug Master Files (DMFs/ASMFs) and complete pharmaceutical dossiers for regulatory submissions. Products are manufactured using both chemical synthesis processes (primarily for iron and steroids) and biological extraction processes from liquids, organs, and animal tissues (for glycosaminoglycans and heparins). All operations strictly adhere to GMP (Good Manufacturing Practices) standards.

Differentiator

Problem solved

Functional benefit

Products and services

• Iron Complexes APIs (Antianemics)

Quantifiable outcome

• R&D growth increased +250% over 2020-2022 period
• +1 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Opocrin: Opocrin is an Italian heparin API manufacturer using biological extraction from animal tissues, making it a direct peer for Biofer's glycosaminoglycan and heparin production line.
• EUROAPI: EUROAPI is the European API leader spun out of Sanofi in 2022, producing a broad portfolio of APIs including steroids, hormones, and complex molecules - directly comparable to Biofer's chemical-synthesis API offering and geographic positioning.
• Hovione: Hovione is a European API manufacturer specializing in small-molecule APIs and complex chemistry, with a comparable focus on quality, regulatory dossiers, and DMF support.
• Shenzhen Hepalink: Shenzhen Hepalink is one of the world's largest heparin API producers, competing directly with Biofer's heparin and glycosaminoglycan lines on global supply.
• CordenPharma: CordenPharma is a global CDMO and API manufacturer offering both synthetic and biological API capabilities, serving pharmaceutical customers worldwide - directly comparable to Biofer's dual-mode manufacturing model.

Broad incumbents

• Siegfried Holding: Siegfried is a Swiss-headquartered API and CDMO platform with broader therapeutic coverage and greater scale, but operates the same B2B API business model serving global pharmaceutical clients.
• Aspen Pharmacare: Aspen is a South African-headquartered pharmaceutical manufacturer with a significant sterile API and heparin franchise, providing a scaled benchmark for Biofer's API ambitions.

Regional players

• Fatro: Fatro is an Italian pharmaceutical manufacturer focused on veterinary and human APIs, sharing Biofer's Italian base and biological extraction heritage, though its primary end market is animal health.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/bioferspa
• LinkedInlinkedin.com/company/bioferspa

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biofer